Roth Capital 'Impressed' by Latest Dupixent Data; Affirms Regeneron (REGN) at 'Buy'
Tweet Send to a Friend
Roth Capital affirms Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) at Buy with a price target of $520 after the company and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
